Daewoong Pharmaceutical Launches High-Dose 'Juplie' for Hand and Foot Nail Fungus Treatment

Daewoong Pharmaceutical announced on the 24th that it has launched an 8ml version of Juplie topical solution, a treatment for onychomycosis (onychomycosis of fingernails and toenails). Developed by Japan's Kaken Pharmaceutical and first launched in 2017 by Dong-A ST, Juplie is the first generic version of Jublia, and the 8ml high-capacity version is an extension of the 4ml Juplie released by Daewoong Pharmaceutical in April.

Daewoong Pharmaceutical's hand and toenail fungus treatment 'Juplie'
[Photo by Daewoong Pharmaceutical]

Onychomycosis is considered a condition that requires consistent treatment. Fingernails require a treatment period of 6 months, and toenails require more than 12 months. The newly launched high-capacity 8ml Juplie by Daewoong Pharmaceutical is expected to help reduce treatment discontinuation rates by providing a longer treatment period per bottle. Additionally, it is more affordable and economical compared to two 4ml bottles, allowing healthcare providers and patients to select the appropriate dosage according to their situation.

Juplie is a prescription medication used for the treatment of onychomycosis caused by dermatophytes. It is a topical solution applied to infected fingernails and toenails. Onychomycosis occurs when dermatophytes, a type of fungus, or other fungi infect the nails, causing fungal infection (mycosis). The main ingredient of Juplie is efinaconazole, which offers advantages such as ▲high permeability without the need for nail filing ▲excellent tolerability through topical action ▲convenient use with an integrated container and brush. Efinaconazole is recommended as a first-line treatment for onychomycosis according to domestic and international guidelines, including the Korean Society for Medical Mycology’s onychomycosis treatment guidelines.

Juplie applies patented technology that allows only the appropriate amount of solution to be dispensed through a brush attached to the container. This prevents leakage and evaporation of the solution, making storage easy. It also prevents excessive solution from flowing out during use, which can cause side effects such as redness and rash when it comes into contact with the skin. Furthermore, its high permeability allows it to be applied over nail polish.

Park Eun-kyung, Head of ETC Marketing Division at Daewoong Pharmaceutical, said, “The domestic antifungal treatment market is worth 330 billion KRW. While oral medications raise concerns about liver toxicity, gastrointestinal side effects, and drug interactions, topical solutions have lower risk of side effects, indicating great market potential. Based on Juplie’s excellent quality, stable supply, and competitive pricing, we aim to provide patients with new options in the onychomycosis treatment market and expand the overall market size.”